Ianalumab reduces Sjögren disease activity
Sarah Onuora
Nature Reviews Rheumatology
· Springer Nature
· 2026-11-10
· DOI: 10.1038/s41584-026-01466-3
Аннотация
Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01466-3 In patients with active Sjögren disease, treatment with ianalumab 300 mg monthly reduced disease activity, but not symptom scores, more than placebo in two phase III clinical trials.
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Ревматология»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
Sarah Onuora. Ianalumab reduces Sjögren disease activity. // Nature Reviews Rheumatology. – 2026. – DOI: 10.1038/s41584-026-01466-3. – URL: https://www.nature.com/articles/s41584-026-01466-3
Sarah Onuora (2026). Ianalumab reduces Sjögren disease activity. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-026-01466-3
Sarah Onuora. “Ianalumab reduces Sjögren disease activity.” Nature Reviews Rheumatology, 2026. doi:10.1038/s41584-026-01466-3.
@article{Onuora2026,
title = {Ianalumab reduces Sjögren disease activity},
author = {Onuora, Sarah},
journal = {Nature Reviews Rheumatology},
year = {2026},
doi = {10.1038/s41584-026-01466-3},
url = {https://www.nature.com/articles/s41584-026-01466-3}
}